Trading View

Observe before you act. Welcome to TradingView, the largest social platform and charting service for traders and investors, with over 30 million active users each month from 180 countries. Supported by leading American venture capital, our team spans more than 40 countries and speaks over 20 languages, and we are experiencing significant growth. Our open-source charts and commercial tools are utilized by thousands of financial websites worldwide, including major players like CME, Refinitiv, Investopedia, Crunchbase, Binance, and Bitcoin.com, among many others. We also rank as one of the largest websites globally, holding the #61 spot on Alexa Rankings. If you have an interest in finance, there's a good chance you've encountered us. Our goal is to empower millions of individuals to achieve success in their lives, however they define it, by delivering top-notch trading and cryptocurrency information in the most effective way. This enables them to make well-informed decisions. We invite passionate individuals to join our team, where product excellence is paramount, and you will have the chance to produce your best work, with your contributions reaching millions every day.

International

English, French, Indonesian, Italian, Portuguese, Spanish, Turkish

Financial/Market news

Outlet metrics

Domain Authority

Ranking

Global

#118

India

#65

Finance/Investing

Traffic sources

Monthly visitors

Articles

Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer Treatment

16 hours ago | tradingview.com | Connor Hart

Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer TreatmentVSTMVerastem Oncology said Wednesday that the Food and Drug Administration cleared the company's investigational new drug application for its potential treatment of certain cancers. The biopharmaceutical company now plans to initiate a Phase 1/2a study for the treatment, VS-7375, in mid-2025.
Trump Says He Has 'No Intention' of Firing Fed Chair Powell

1 day ago | tradingview.com | Vicky Huang

Trump Says He Has 'No Intention' of Firing Fed Chair Powell By Vicky Ge HuangPresident Trump said he isn't planning to dismiss Federal Reserve Chair Jerome Powell and signaled that tariffs on China could be cut. For many on Wall Street, the smoking gun signaling capital flight from the U.S. is that the S&P 500 and the dollar have often sold off simultaneously this month.
AT&T Posts Higher 1Q Profit, Revenue After Adding More Fiber, 5G Customers

1 day ago | tradingview.com | Connor Hart

AT&T Posts Higher 1Q Profit, Revenue After Adding More Fiber, 5G CustomersTAT&T logged higher profit and revenue in the first quarter, boosted in part by an increase in acquired customers. The telecommunications company on Wednesday posted net income attributable to common stock of $4.4 billion, or 61 cents a share, compared with $3.4 billion, or 47 cents a share, a year earlier. Adjusted per-share earnings came in at 51 cents, in line with the expectations of analysts polled by FactSet.
Thermo Fisher 1Q Net, Revenue Up, Costs Stable

1 day ago | tradingview.com | Rob Curran

Thermo Fisher 1Q Net, Revenue Up, Costs StableTMOThermo Fisher Scientific posted 14% net-income growth in the first quarter as revenue inched up and costs remained stable. The Waltham, Mass., maker of microscopes and other life-sciences and laboratory equipment said earnings rose to $1.51 billion, or $3.98 a share, from $1.33 billion, or $3.46 a share, a year earlier.
Northrop Grumman Trims 2025 Outlook Following Slower Sales, Higher Bomber-Program CostsUpdate

1 day ago | tradingview.com | Denny Jacob |Rob Curran

Northrop Grumman Trims 2025 Outlook Following Slower Sales, Higher Bomber-Program CostsUpdateNOCBy Denny Jacob and Rob CurranNorthrop Grumman first-quarter earnings and sales missed analysts' estimates as delayed awards and higher-than-expected costs weighed on results, prompting it to cut its outlook for the year.
Chipotle to Open Mexico Location, Testing Expansion into Latin AmericaUpdate

2 days ago | tradingview.com | Denny Jacob

Chipotle to Open Mexico Location, Testing Expansion into Latin AmericaUpdateCMGChipotle Mexican Grill will open a storefront in Mexico and look to expand into additional markets in the region. The burrito chain on Monday said it signed a development agreement with Alsea, a restaurant operator in Latin America and Europe, to open a location in Mexico by early 2026.
DHL Suspends High-Value Deliveries to U.S. Consumers Amid Tariff Turmoil

3 days ago | tradingview.com | Kimberley Kao

DHL Suspends High-Value Deliveries to U.S. Consumers Amid Tariff TurmoilDHLDeutsche Post is suspending high-value shipments to the U.S., effective Monday, as it struggles with delays from customs clearances amid the new U.S. rules. The company, which trades as DHL Group, said in a statement that a "surge in formal customs clearances, which we are handling around the clock" for goods valued at more than $800, regardless of where they were shipped from, may cause multiday delays.
Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan

5 days ago | tradingview.com | Connor Hart

Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing PlanREGNRegeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the company's proposal to extend the interval between doses.
Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

5 days ago | tradingview.com | Denny Jacob

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market LaunchLLYEli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.
Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU

5 days ago | tradingview.com | Colin Kellaher

Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSUSANREGNRegeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic spontaneous urticaria, or CSU. Regeneron and Sanofi on Friday said the approval covers Dupixent in people 12 and older who have CSU and remain symptomatic despite histamine-1 antihistamine treatment.